Stoke Therapeutics (NASDAQ:STOK) Shares Up 10.3% - Time to Buy?

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s stock price rose 10.3% during trading on Tuesday . The stock traded as high as $10.90 and last traded at $10.93. Approximately 899,462 shares were traded during trading, an increase of 28% from the average daily volume of 703,910 shares. The stock had previously closed at $9.91.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Chardan Capital reiterated a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Finally, HC Wainwright decreased their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $23.20.

Stoke Therapeutics Stock Performance

The company has a 50-day simple moving average of $8.77 and a two-hundred day simple moving average of $9.66. The firm has a market capitalization of $608.21 million, a P/E ratio of -5.30 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company's stock, valued at $554,550.54. The trade was a 5.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,748 shares of company stock valued at $225,687. 11.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after purchasing an additional 5,084 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Stoke Therapeutics during the fourth quarter valued at $63,000. AlphaQuest LLC bought a new stake in Stoke Therapeutics in the 1st quarter worth about $72,000. US Bancorp DE raised its position in Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after buying an additional 11,108 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in shares of Stoke Therapeutics during the first quarter valued at approximately $92,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.